US Patent 8,980,901 (Drug) Scope, Claims, and US Landscape
What is US Drug Patent 8,980,901 claiming?
US Patent 8,980,901 is directed to methods of treating human hematological malignancies by administering a specific compound (or pharmaceutically acceptable salt). The independent method claims are broad “treating” claims centered on a compound identity rather than a dosing regimen, patient biomarker, line of therapy, or treatment combination.
Claim architecture (as provided)
The claims you provided fall into two main sets:
-
“Compound selected from the group consisting of …” with explicit dependent embodiments
- Claims 1-9 cover treating hematological malignancies using a compound selected from a defined group (your excerpt truncates the actual compound recitation for claims 1 and 8).
- Dependent claims specify malignancy type (leukemia/lymphoma; non-Hodgkin’s; Hodgkin’s; lymphocytic leukemia; multiple myeloma).
- Dependent claims also specify an “S-enantiomer” and a pharmaceutical composition (excipient + compound).
-
“Compound having the structure: …” with explicit dependent embodiments
- Claims 10-21 similarly claim treatment using a compound defined by chemical structure (your excerpt truncates the structure content for claims 10, 16).
- Dependent claims specify the same malignancy subsets.
Scope created by the claim language
Because all provided claims are framed as:
- “A method of treating a hematological malignancy in a human comprising administering … a compound … or a pharmaceutically acceptable salt thereof,”
the enforceable scope is primarily:
- Indication scope: hematological malignancies including leukemia and lymphoma (with dependent subtypes) and multiple myeloma.
- Act scope: administration of the compound (or salt).
- Form scope: includes S-enantiomer (for claims 7 and 9).
- Product scope (indirectly): includes administration of a composition containing excipient(s) plus the compound (claim 8).
Notably absent from your excerpted claim set:
- specific dose, frequency, duration, or regimen sequencing;
- requirement for combination partners (other than the excipient content in claim 8);
- requirement for patient selection beyond the malignancy category.
What do the independent claim sets cover?
H2: What is the core coverage of Claims 1-9?
Claim 1 is the first independent method claim: it covers a method of treating hematological malignancy by administering a compound that is selected from a defined group (truncated in your excerpt) or a pharmaceutically acceptable salt.
Claims 2-6 narrow the malignancy type to:
- leukemia and lymphoma (claim 2)
- non-Hodgkin’s lymphoma (claim 3)
- Hodgkin’s lymphoma (claim 4)
- lymphocytic leukemia (claim 5)
- multiple myeloma (claim 6)
Claim 7 narrows the compound to:
Claim 8 adds a composition requirement:
- administer a pharmaceutical composition comprising
- at least one pharmaceutically acceptable excipient, and
- the compound (or a pharmaceutically acceptable salt)
Claim 9 again ties the compound to:
Practical implication: Claims 1 and 10/16 (structure-defined) are the broadest. Claims 7/9 add an extra discriminator (enantiomer), which can matter if alternative enantiomeric forms exist in the market or pipelines.
H2: What is the core coverage of Claims 10-21?
Claim 10 is the second independent method claim: it covers treating hematological malignancy by administering a compound having a specified structure (truncated in your excerpt) or a pharmaceutically acceptable salt.
Claims 11-15 mirror claim 2-6:
- leukemia and lymphoma (claim 11)
- non-Hodgkin’s lymphoma (claim 12)
- Hodgkin’s lymphoma (claim 13)
- lymphocytic leukemia (claim 14)
- multiple myeloma (claim 15)
Claims 16-21 repeat the method structure with the structure-defined compound:
- claim 16 independent
- claims 17-21 mirror claim 11-15 again
Practical implication: Claims 10 and 16 create two separate structural claim anchors (even if they appear duplicative in your excerpt). In litigation, the “structure-defined” anchor typically lets the patentee argue infringement based on chemical identity, not only on membership in a “group” definition (as in claim 1).
Claim-by-claim scope summary (based on your excerpt)
| Claim |
What is required (minimum) |
What it narrows (if dependent) |
Enforceability emphasis |
| 1 |
Treat hematological malignancy by administering a compound from a defined group or salt |
baseline |
Broadest independent “group” anchor |
| 2 |
As claim 1 |
leukemia or lymphoma |
Indication narrowing |
| 3 |
As claim 1 |
non-Hodgkin’s lymphoma |
Indication narrowing |
| 4 |
As claim 1 |
Hodgkin’s lymphoma |
Indication narrowing |
| 5 |
As claim 1 |
lymphocytic leukemia |
Indication narrowing |
| 6 |
As claim 1 |
multiple myeloma |
Indication narrowing |
| 7 |
As claim 1 |
compound is S-enantiomer |
S-form discriminator |
| 8 |
As claim 1 |
administer composition with excipient + compound/salt |
Dosage-form packaging requirement |
| 9 |
As claim 8 |
compound is S-enantiomer |
S-form + composition coupling |
| 10 |
Treat hematological malignancy by administering structure-defined compound or salt |
baseline (structure anchor) |
Broadest independent “structure” anchor |
| 11 |
As claim 10 |
leukemia or lymphoma |
Indication narrowing |
| 12 |
As claim 10 |
non-Hodgkin’s lymphoma |
Indication narrowing |
| 13 |
As claim 10 |
Hodgkin’s lymphoma |
Indication narrowing |
| 14 |
As claim 10 |
lymphocytic leukemia |
Indication narrowing |
| 15 |
As claim 10 |
multiple myeloma |
Indication narrowing |
| 16 |
Treat hematological malignancy by administering structure-defined compound or salt |
baseline (second structure claim set) |
Broad structural anchor |
| 17 |
As claim 16 |
leukemia or lymphoma |
Indication narrowing |
| 18 |
As claim 16 |
non-Hodgkin’s lymphoma |
Indication narrowing |
| 19 |
As claim 16 |
Hodgkin’s lymphoma |
Indication narrowing |
| 20 |
As claim 16 |
lymphocytic leukemia |
Indication narrowing |
| 21 |
As claim 16 |
multiple myeloma |
Indication narrowing |
What is the infringement “pressure point” created by these claims?
H2: Which product/process attributes matter most?
Based on the claims provided, the infringement pressure points are:
- Chemical identity match
- The compound must either match the defined group (claim 1) or match the specified structure (claims 10 and 16).
- Salt coverage
- “pharmaceutically acceptable salt” is included for every independent anchor (claims 1, 10, 16).
- Enantiomer form (S)
- Claims 7 and 9 narrow to the S-enantiomer. If an infringing product uses a different stereoisomer, these narrower claims are easier to design around, while the broadest independent claims may still be asserted depending on whether the independent anchors already cover other stereoisomers (your excerpt does not show whether claims 1/10/16 already implicitly require S).
- Indication alignment
- All claims are limited to “hematological malignancy in a human,” with dependent narrowing to leukemia/lymphoma subsets and multiple myeloma.
- Composition/excipient
- Claim 8 requires a composition with excipients, but in practice most marketed oral or injectable dosage forms include excipients, so this limitation often maps onto standard formulation reality.
What is the “claim scope” in practical market terms?
H2: What disease areas are covered by the dependent claim set?
From the excerpt, covered malignancies are:
- Leukemia and lymphoma (claims 2, 11, 17)
- Non-Hodgkin’s lymphoma (claims 3, 12, 18)
- Hodgkin’s lymphoma (claims 4, 13, 19)
- Lymphocytic leukemia (claims 5, 14, 20)
- Multiple myeloma (claims 6, 15, 21)
The claim set is therefore built to capture broad hematologic oncology use, with dependent claims providing disease-specific hooks that can be paired with label indications, trial protocols, and physician prescribing practices.
What is the patent landscape impact in the US?
H2: How would this patent typically sit in a US lifecycle?
With only the claim text provided, the landscape assessment can only be framed at the claim-type level:
- It is a method-of-treatment patent covering administration of a compound to treat hematologic malignancies.
- It likely creates therapeutic-use coverage that can reach:
- branded products using the compound,
- generic/salt/enantiomer variants if they practice the claimed method,
- follow-on formulations that still administer the claimed compound (since claim 8 ties only to inclusion of excipient).
H2: What design-arounds are suggested by the claim drafting (based on excerpt)?
The most plausible design-arounds implied by the provided claims are:
- S-enantiomer avoidance to target claims 7 and 9 specifically.
- Non-hematological indication selection (if a product is only studied/marketed for non-hematologic diseases, the direct dependent hooks are harder to invoke).
- Non-structure/non-group chemical identity (avoidance of the claimed compound is the strongest escape, but it is not a “regimen” design-around).
What the excerpt does not show:
- any explicit exclusion of combination regimens; therefore, combination use does not inherently avoid infringement unless it avoids administration of the claimed compound or avoids the claimed indication.
Key Takeaways
- US 8,980,901 is a hematologic oncology method-of-treatment patent centered on administering a specific compound (or pharmaceutically acceptable salt) to humans.
- The claim set has two independent anchor sets: one defined by a compound group (claims 1-9) and one defined by chemical structure (claims 10-21).
- The disease scope in dependent claims covers leukemia, lymphoma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, lymphocytic leukemia, and multiple myeloma.
- Enantiomer specificity exists for the S-enantiomer in claims 7 and 9, creating a narrower target for any stereoisomer-variant strategy.
- Composition with excipient is required in claim 8, but typical dosage forms will satisfy this.
FAQs
1) Does US 8,980,901 require a specific dosing regimen?
No dosing schedule is specified in the excerpted claims. The claims are centered on administering the compound (or salt) for treating hematological malignancies.
2) Are both salts and the free base covered?
Yes. Each independent anchor is written to include “a pharmaceutically acceptable salt thereof.”
3) Which cancer subtypes are explicitly named?
Non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, lymphocytic leukemia, and multiple myeloma are explicitly recited in dependent claims; leukemia and lymphoma are also recited more broadly.
4) Do any claims require the S-enantiomer?
Yes. Claims 7 and 9 limit the compound to the S-enantiomer.
5) Can infringement be avoided by changing the formulation excipient?
Claim 8 requires a composition with “at least one pharmaceutically acceptable excipient” plus the compound. Most standard formulations include such excipients, so changing excipients alone is unlikely to avoid the claim as drafted in the excerpt.
References
[1] United States Patent Application/Publication data for US 8,980,901 (claims as provided in prompt).
